Espicom


The Pharmaceutical Market: Indonesia

Published 04 July 2014

  • 145 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Indonesia

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts
29
OTC Medicine Market Forecast
30
Table: OTC Medicine Sales By Category, 2004-2010
32
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
32
Pharmaceutical Trade Forecast
33
Table: Pharmaceutical Trade Data And Forecast (US$mn)
35
Table: Pharmaceutical Trade Data And Forecasts (IDRmn)
36
Other Healthcare Data
37
Key Risks To BMI's Forecast Scenario
37
Macroeconomic Forecasts
39
Economic Analysis
39
Table: Indonesia - Economic Activity
42
Industry Risk Reward Ratings
43
Asia Risk/Reward Ratings
43
Indonesia Risk/Reward Ratings
49
Rewards
49
Risks
50
Market Overview
51
Industry Trends And Developments
52
Epidemiology
52
Non-Communicable Diseases
53
Communicable Diseases
53
HIV/AIDS
54
Public Health Developments
56
Table: UN Millennium Development Goals For Indonesia
56
Healthcare System
57
Health Insurance
58
Health Insurance Developments
60
Healthcare System Reform
61
Medical Tourism
62
Research & Development
62
Clinical Trials
63
Herbal Medicines
65
Regulatory Development
66
Pharmaceutical Advertising
68
Regional Harmonisation
69
Intellectual Property Issues
70
Halal Medicine Regulations
73
Labelling Requirements
74
Compulsory Licensing
74
Counterfeit Drugs
75
Generic Drug Legislation
76
Free Trade Agreements
77
Pricing Regime
77
Reimbursement Regime
79
Competitive Landscape
80
Pharmaceutical Industry
80
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions
81
Table: Top-10 Pharmaceutical Companies According To Market Capitalisation
82
Domestic Industry
82
Foreign Industry
84
Recent Pharmaceutical Industry Developments
84
Pharmaceutical Wholesale
85
Pharmaceutical Retail
86
Company Profile
89
Soho Group
89
Darya-Varia Group
92
PT Kalbe Farma
95
PT Biofarma
99
Kimia Farma
103
Combiphar PT
107
Indopharma
109
Sanofi
112
Pfizer
115
Novartis
118
GlaxoSmithKline
121
Merck & Co
124
Bayer
128
Merck Group
131
Demographic Forecast
134
Table: Indonesia's Population By Age Group, 1990-2020 ('000)
135
Table: Indonesia's Population By Age Group, 1990-2020 (% of total)
136
Table: Indonesia's Key Population Ratios, 1990-2020
137
Table: Indonesia's Rural And Urban Population, 1990-2020
137
Glossary
138
Methodology
140
Pharmaceutical Expenditure Forecast Model
140
Healthcare Expenditure Forecast Model
140
Notes On Methodology
141
Risk/Reward Ratings Methodology
142
Ratings Overview
143
Table: Pharmaceutical Risk/Reward Ratings Indicators
143
Indicator Weightings
144
OVERVIEW OF THE PHARMACEUTICAL MARKET IN INDONESIA

Indonesia's new goal to establish universal healthcare coverage by 2019 rather than 2014 is more feasible given that the programme will be rolled out in phases. We continue to see universal healthcare coverage as a key theme in Asia, although poor governance in several countries across the region will delayitsimplementation. Despite this, pharmaceutical firms will continue to enjoy strong growth in the region due to the expanding, increasingly ageing and affluent population, which will boost volume demand for pharmaceuticals as well as medical services across the board.

HeadlineExpenditure Projections

Pharmaceuticals: IDR53,041bn (US$6.04bn) in 2011 to IDR58,657bn (US$6.25bn) in 2012; +10.6% growth in local currency terms and +3.5% in US dollar terms. Local currency forecastbroadlyunchanged from previous quarter.

Healthcare: IDR195,355bn (US$22.26bn) in 2011 to IDR223,454bn (US$23.82bn) in 2012; +14.4% growth in local currency terms and +7.0% in US dollar terms. Local currency forecastunchanged from previous quarter.

Medicaldevices: IDR5,721bn (US$652mn) in 2011 to IDR6,282bn (US$670mn) in 2012; +9.8% growth in local currency terms and +2.7% in US dollar terms. Local currency forecastbroadlyunchanged from previous quarter.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%